WO2023172991A3 - Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies - Google Patents

Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies Download PDF

Info

Publication number
WO2023172991A3
WO2023172991A3 PCT/US2023/063998 US2023063998W WO2023172991A3 WO 2023172991 A3 WO2023172991 A3 WO 2023172991A3 US 2023063998 W US2023063998 W US 2023063998W WO 2023172991 A3 WO2023172991 A3 WO 2023172991A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen receptor
chimeric antigen
icar
acar
bicistronic
Prior art date
Application number
PCT/US2023/063998
Other languages
French (fr)
Other versions
WO2023172991A2 (en
Inventor
Rick KENDALL
Frank CALZONE
Orit Foord
Gregor B. Adams
Jason Yi
Adi SHARBI-YUNGER
Tanya KIM
David BASSAN
Original Assignee
Immpact Bio Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immpact Bio Usa, Inc. filed Critical Immpact Bio Usa, Inc.
Publication of WO2023172991A2 publication Critical patent/WO2023172991A2/en
Publication of WO2023172991A3 publication Critical patent/WO2023172991A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the field of cancer immunotherapy by employing bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer treatment therapies. The invention further relates to bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs that limit off-target effects when used in cancer treatment therapies.
PCT/US2023/063998 2022-03-09 2023-03-08 Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies WO2023172991A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263318353P 2022-03-09 2022-03-09
US63/318,353 2022-03-09
US202263321620P 2022-03-18 2022-03-18
US63/321,620 2022-03-18

Publications (2)

Publication Number Publication Date
WO2023172991A2 WO2023172991A2 (en) 2023-09-14
WO2023172991A3 true WO2023172991A3 (en) 2023-11-02

Family

ID=87935971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/063998 WO2023172991A2 (en) 2022-03-09 2023-03-08 Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies

Country Status (1)

Country Link
WO (1) WO2023172991A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019056099A1 (en) * 2017-09-19 2019-03-28 The University Of British Columbia Anti-hla-a2 antibodies and methods of using the same
US20200316120A1 (en) * 2018-09-28 2020-10-08 Immpact-Bio Ltd. METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES
WO2021119489A1 (en) * 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2022051727A2 (en) * 2020-09-04 2022-03-10 Immpact-Bio Ltd. BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (aCAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019056099A1 (en) * 2017-09-19 2019-03-28 The University Of British Columbia Anti-hla-a2 antibodies and methods of using the same
US20200316120A1 (en) * 2018-09-28 2020-10-08 Immpact-Bio Ltd. METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES
WO2021119489A1 (en) * 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2022051727A2 (en) * 2020-09-04 2022-03-10 Immpact-Bio Ltd. BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (aCAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies

Also Published As

Publication number Publication date
WO2023172991A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
EP4269594A3 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
EP3802798A4 (en) Chimeric antigen receptor t cells (car-t) for the treatment of cancer
WO2020065406A3 (en) Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies
WO2018023025A8 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
WO2018098306A8 (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
AU2018291128A1 (en) Anti-B-cell maturation antigen chimeric antigen receptors with human domains
WO2022051727A3 (en) BICISTRONIC INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR)/ACTIVATING CHIMERIC ANTIGEN RECEPTOR (aCAR) CONSTRUCTS FOR USE IN CANCER THERAPIES
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
AU2016245958A8 (en) CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
EP3552665A3 (en) Antibodies
PH12020552229A1 (en) Il-11ra antibodies
AU2018278321A1 (en) Chimeric antigen receptors targeting FLT3
WO2021007428A3 (en) Molecules, compositions and methods for treatment of cancer
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
WO2019232409A9 (en) Methods for genome editing and activation of cells
WO2020252208A3 (en) Macrophage specific engager compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767675

Country of ref document: EP

Kind code of ref document: A2